The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 31, 2013
Filed:
May. 05, 2005
Sylvain Chemtob, Côte St-Luc, CA;
Christiane Quiniou, Montréal, CA;
William D. Lubell, Montréal, CA;
Martin Beauchamp, Montréal, CA;
Karl A. Hansford, Montréal, CA;
Sylvain Chemtob, Côte St-Luc, CA;
Christiane Quiniou, Montréal, CA;
William D. Lubell, Montréal, CA;
Martin Beauchamp, Montréal, CA;
Karl A. Hansford, Montréal, CA;
Valorisation-Rechereche Société en Commandite, Montreal, CA;
Valorisation HSJ, Société en Commandite, Montreal, CA;
Abstract
Peptides that are designed to inhibit the biological activity of the IL-1R type 1 receptor and inhibit IL-1R/IL-1RacP related cell signaling and biological activity are disclosed. Compositions comprising IL-1R antagonists of the present invention are useful in the treatment of IL-1 related diseases or conditions such as arthritis, rheumatoid arthritis, osteoarthritis, and inflammatory bowel disease as well as other chronic or acute inflammatory diseases. This invention also discloses an isolated compound having an IL-1R antagonist activity, said compound being selected from the group consisting of: a peptide comprising the amino acid sequence RYTPELX, wherein R, Y, T, P, E, L, refer to their corresponding amino acids, and X is selected from no amino acid and alanine (A); and a derivative of (a) wherein the derivative incorporates one, two or three amino acid modification selected from an amino acid addition, deletion or substitution in the RYTPEL portion of the peptide, and wherein said derivative maintains its antagonist IL-1R activity.